Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 29 12 2018
revised: 09 02 2019
accepted: 14 02 2019
pubmed: 6 5 2019
medline: 12 7 2019
entrez: 7 5 2019
Statut: ppublish

Résumé

The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships. The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods. Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up). Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV. National Institute for Health Research.

Sections du résumé

BACKGROUND
The level of evidence for HIV transmission risk through condomless sex in serodifferent gay couples with the HIV-positive partner taking virally suppressive antiretroviral therapy (ART) is limited compared with the evidence available for transmission risk in heterosexual couples. The aim of the second phase of the PARTNER study (PARTNER2) was to provide precise estimates of transmission risk in gay serodifferent partnerships.
METHODS
The PARTNER study was a prospective observational study done at 75 sites in 14 European countries. The first phase of the study (PARTNER1; Sept 15, 2010, to May 31, 2014) recruited and followed up both heterosexual and gay serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex, whereas the PARTNER2 extension (to April 30, 2018) recruited and followed up gay couples only. At study visits, data collection included sexual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV-positive partner). If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis was done to compare HIV-1 pol and env sequences in both partners to identify linked transmissions. Couple-years of follow-up were eligible for inclusion if condomless sex was reported, use of pre-exposure prophylaxis or post-exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was virally suppressed (plasma HIV-1 RNA <200 copies per mL) at the most recent visit (within the past year). Incidence rate of HIV transmission was calculated as the number of phylogenetically linked HIV infections that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods.
FINDINGS
Between Sept 15, 2010, and July 31, 2017, 972 gay couples were enrolled, of which 782 provided 1593 eligible couple-years of follow-up with a median follow-up of 2·0 years (IQR 1·1-3·5). At baseline, median age for HIV-positive partners was 40 years (IQR 33-46) and couples reported condomless sex for a median of 1·0 years (IQR 0·4-2·9). During eligible couple-years of follow-up, couples reported condomless anal sex a total of 76 088 times. 288 (37%) of 777 HIV-negative men reported condomless sex with other partners. 15 new HIV infections occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions, resulting in an HIV transmission rate of zero (upper 95% CI 0·23 per 100 couple-years of follow-up).
INTERPRETATION
Our results provide a similar level of evidence on viral suppression and HIV transmission risk for gay men to that previously generated for heterosexual couples and suggest that the risk of HIV transmission in gay couples through condomless sex when HIV viral load is suppressed is effectively zero. Our findings support the message of the U=U (undetectable equals untransmittable) campaign, and the benefits of early testing and treatment for HIV.
FUNDING
National Institute for Health Research.

Identifiants

pubmed: 31056293
pii: S0140-6736(19)30418-0
doi: 10.1016/S0140-6736(19)30418-0
pmc: PMC6584382
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2428-2438

Subventions

Organisme : Department of Health
Pays : United Kingdom

Investigateurs

Pep Coll (P)
Patricia Cobarsi (P)
Aroa Nieto (A)
Michael Meulbroek (M)
Antonia Carrillo (A)
Jorge Saz (J)
Jorge D R Guerrero (JDR)
Mar Vera García (MV)
Felix Gutiérrez (F)
Mar Masiá (M)
Catalina Robledano (C)
Agathe Leon (A)
Lorna Leal (L)
Eva G Redondo (EG)
Vicente P Estrada (VP)
Rocio Marquez (R)
Raquel Sandoval (R)
Pompeyo Viciana (P)
Nuria Espinosa (N)
Luis Lopez-Cortes (L)
Daniel Podzamczer (D)
Juan Tiraboschi (J)
Sandra Morenilla (S)
Antonio Antela (A)
Elena Losada (E)
Nneka Nwokolo (N)
Janey Sewell (J)
Amanda Clarke (A)
Sarah Kirk (S)
Alyson Knott (A)
Alison J Rodger (AJ)
Thomas Fernandez (T)
Mark Gompels (M)
Louise Jennings (L)
Lana Ward (L)
Julie Fox (J)
Julianne Lwanga (J)
Ming Lee (M)
Richard Gilson (R)
Clifford Leen (C)
Sheila Morris (S)
Dan Clutterbuck (D)
Michael Brady (M)
David Asboe (D)
Serge Fedele (S)
Sarah Fidler (S)
Norbert Brockmeyer (N)
Anja Potthoff (A)
Adriane Skaletz-Rorowski (A)
Johannes Bogner (J)
Ulrich Seybold (U)
Julia Roider (J)
Heiko Jessen (H)
Arne Jessen (A)
Slobodan Ruzicic (S)
Hans-Jürgen Stellbrink (HJ)
Tim Kümmerle (T)
Clara Lehmann (C)
Olaf Degen (O)
Sindy Bartel (S)
Anja Hüfner (A)
Jürgen Rockstroh (J)
Karina Mohrmann (K)
Christoph Boesecke (C)
Ivanka Krznaric (I)
Patrick Ingiliz (P)
Rainer Weber (R)
Christina Grube (C)
Dominique Braun (D)
Huldrych Günthard (H)
Gilles Wandeler (G)
Hansjakob Furrer (H)
Andri Rauch (A)
Pietro Vernazza (P)
Patrick Schmid (P)
Manuela Rasi (M)
Denise Borso (D)
Markus Stratmann (M)
Oliver Caviezel (O)
Marcel Stoeckle (M)
Manuel Battegay (M)
Philip Tarr (P)
Vanessa Christinet (V)
Florent Jouinot (F)
Camille Isambert (C)
Enos Bernasconi (E)
Beatrice Bernasconi (B)
Jan Gerstoft (J)
Lene P Jensen (LP)
Anne A Bayer (AA)
Lars Ostergaard (L)
Yordanos Yehdego (Y)
Ann Bach (A)
Pia Handberg (P)
Gitte Kronborg (G)
Svend S Pedersen (SS)
Nete Bülow (N)
Bente Ramskover (B)
Matti Ristola (M)
Outi Debnam (O)
Jussi Sutinen (J)
Anders Blaxhult (A)
Ronnie Ask (R)
Bernt Hildingsson-Lundh (B)
Katarina Westling (K)
Eeva-Maija Frisen (EM)
Gráinne Cortney (G)
Siobhan O'Dea (S)
Stephane De Wit (S)
Coca Necsoi (C)
Linos Vandekerckhove (L)
Jean-Christophe Goffard (JC)
Sophie Henrard (S)
Jan Prins (J)
Hans-Henrik Nobel (HH)
Annouschka Weijsenfeld (A)
Arne Van Eeden (A)
Loek Elsenburg (L)
Kees Brinkman (K)
Danielle Vos (D)
Imke Hoijenga (I)
Elisabeth Gisolf (E)
Petra Van Bentum (P)
Dominique Verhagen (D)
Francois Raffi (F)
Eric Billaud (E)
Michel Ohayon (M)
Daniel Gosset (D)
Alexandre Fior (A)
Gilles Pialoux (G)
Pelagie Thibaut (P)
Julie Chas (J)
Vincent Leclercq (V)
Vincent Pechenot (V)
Vincent Coquelin (V)
Christian Pradier (C)
Sophie Breaud (S)
Veronique Touzeau-Romer (V)
Armin Rieger (A)
Maria Kitchen-Maria Geit (M)
Mario Sarcletti (M)
Martin Gisinger (M)
Angela Oellinger (A)
Andrea Antinori (A)
Samanta Menichetti (S)
Teresa Bini (T)
Cristina Mussini (C)
Marianna Meschiari (M)
Antonio Di Biagio (A)
Lucia Taramasso (L)
Benedetto M Celesia (BM)
Maria Gussio (M)
Nuno Janeiro (N)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
Lancet HIV. 2017 Nov;4(11):e475
pubmed: 29096785
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
Antivir Ther. 2008;13(5):641-2
pubmed: 18771047
Sci Transl Med. 2011 Apr 6;3(77):77ra29
pubmed: 21471433
J Infect Dis. 1998 Feb;177(2):320-30
pubmed: 9466517
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Int J Epidemiol. 2010 Aug;39(4):1048-63
pubmed: 20406794
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):112-116
pubmed: 27532476
HIV Med. 2019 Mar;20 Suppl 2:s2-s80
pubmed: 30869189
Sex Transm Dis. 2008 Nov;35(11):912-5
pubmed: 18607309
Virus Res. 2012 Jun;166(1-2):54-60
pubmed: 22429620
J Antimicrob Chemother. 2014 Apr;69(4):1090-7
pubmed: 24284781
JAMA. 2016 Nov 15;316(19):2045
pubmed: 27838717
Sex Transm Dis. 2008 Jan;35(1):55-60
pubmed: 18217225
AIDS. 2012 May 15;26(8):971-5
pubmed: 22382146
Lancet. 2010 Jun 12;375(9731):2092-8
pubmed: 20537376
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
Antivir Ther. 2008;13(5):729-32
pubmed: 18771057
J Infect Dis. 2016 Jul 15;214(2):212-5
pubmed: 27053765
BMC Public Health. 2012 Jun 25;12:296
pubmed: 22520171
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):579-84
pubmed: 27070123
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
Lancet HIV. 2017 Jul;4(7):e295-e302
pubmed: 28479492
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
pubmed: 16123689

Auteurs

Alison J Rodger (AJ)

Institute for Global Health, University College London, London, UK. Electronic address: alison.rodger@ucl.ac.uk.

Valentina Cambiano (V)

Institute for Global Health, University College London, London, UK.

Tina Bruun (T)

Department of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Pietro Vernazza (P)

Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, St Gallen, Switzerland.

Simon Collins (S)

HIV i-Base, London, UK.

Olaf Degen (O)

University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Giulio Maria Corbelli (GM)

European AIDS Treatment Group, Brussels, Belgium.

Vicente Estrada (V)

Hospital Clinico San Carlos and Universidad Complutense, Madrid, Spain.

Anna Maria Geretti (AM)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.

Apostolos Beloukas (A)

Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Department of Biomedical Sciences, University of West Attica, Athens, Greece.

Dorthe Raben (D)

Department of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Pep Coll (P)

AIDS Research Institute-IrsiCaixa, Hospital Universitari Germans Trias i Pujol and BCN Checkpoint, Badalona and Barcelona, Spain.

Andrea Antinori (A)

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy.

Nneka Nwokolo (N)

Chelsea and Westminster NHS Foundation Trust, London, UK.

Armin Rieger (A)

Medical University of Vienna, Vienna, Austria.

Jan M Prins (JM)

Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Anders Blaxhult (A)

Venhälsan, Södersjukhuset, Stockholm, Sweden.

Rainer Weber (R)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Arne Van Eeden (A)

DC Klinieken, Amsterdam, Netherlands.

Norbert H Brockmeyer (NH)

Centre for Sexual Health and Medicine, Walk in Ruhr, Ruhr University Bochum, Bochum, Germany.

Amanda Clarke (A)

Brighton and Sussex University Hospitals NHS Trust, and Brighton and Sussex Medical School, Brighton, UK.

Jorge Del Romero Guerrero (J)

Centro Sanitario Sandoval, Madrid, Spain.

Francois Raffi (F)

Infectious Diseases Department, University Hospital (Centre Hospitalier Universitaire de Nantes) Hotel-Dieu, and INSERM UIC 1413 Nantes University, Nantes, France.

Johannes R Bogner (JR)

Medizinische Klinik und Poliklinik IV, University Hospital Munich, Munich, Germany.

Gilles Wandeler (G)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

Jan Gerstoft (J)

Rigshospitalet, Copenhagen, Denmark.

Felix Gutiérrez (F)

Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain.

Kees Brinkman (K)

Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands.

Maria Kitchen (M)

Medical University Innsbruck, Innsbruck, Austria.

Lars Ostergaard (L)

Aarhus University Hospital, Skejby, Denmark.

Agathe Leon (A)

Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Matti Ristola (M)

Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Heiko Jessen (H)

Praxis Jessen(2) + Kollegen, Berlin, Germany.

Hans-Jürgen Stellbrink (HJ)

ICH Study Centre, Hamburg, Germany.

Andrew N Phillips (AN)

Institute for Global Health, University College London, London, UK.

Jens Lundgren (J)

Department of Infectious Diseases (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH